Combination Chemotherapy With or Without Capecitabine and/or Trastuzumab Before Surgery in Treating Women With Stage I, Stage II, or Stage III Breast Cancer

Clinical Trial ID NCT00288002

Rank	Title	Journal	Year	PubWeight™‹?›
1	Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.	J Clin Oncol	2012	8.74
2	Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study.	J Clin Oncol	2010	2.54
3	Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study.	J Clin Oncol	2010	1.33
4	Combining mTOR Inhibitors with Chemotherapy and Other Targeted Therapies in Advanced Breast Cancer: Rationale, Clinical Experience, and Future Directions.	Breast Cancer (Auckl)	2013	1.02
5	Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro).	Ann Oncol	2013	0.84
6	Thymosin beta 15A (TMSB15A) is a predictor of chemotherapy response in triple-negative breast cancer.	Br J Cancer	2012	0.77
7	Cohort Selection and Management Application Leveraging Standards-based Semantic Interoperability and a Groovy DSL.	AMIA Jt Summits Transl Sci Proc	2016	0.75
8	Resistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategies.	Ther Adv Med Oncol	2016	0.75